Stockscreener 앱 받기
18.12
4.28%
-0.7986
전일 마감가:
$18.92
열려 있는:
$18.76
하루 거래량:
1.88M
Relative Volume:
0.62
시가총액:
$787.49M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-15.49
EPS:
-1.17
순현금흐름:
$-33.33M
1주 성능:
-2.06%
1개월 성능:
-11.96%
6개월 성능:
+187.92%
1년 성능:
+520.21%
1일 변동 폭
$17.02
$20.03
1주일 범위
$17.02
$20.03
52주 변동 폭
$2.90
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CAPR | 18.14 | 787.49M | 27.10M | -24.31M | -33.33M | -1.17 |
| VRTX | 449.25 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
HC Wainwright Brokers Increase Earnings Estimates for CAPR - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartz
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
CAPRCapricor Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Capricor Therapeutics to Present Exosome Platform Updates - GlobeNewswire
Capricor's StealthX Platform Shows Promise in DMD Treatment, Shares New Data | CAPR Stock News - StockTitan
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $24.67 Average Price Target from Analysts - Defense World
Objective long/short (CAPR) Report - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6%What's Next? - MarketBeat
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Wednesday - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline - Yahoo Finance
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 - The Manila Times
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 3.3%Time to Sell? - MarketBeat
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength - Yahoo Finance
Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment - Benzinga
Piper Sandler Initiates Coverage of Capricor Therapeutics (CAPR) with Overweight Recommendation - MSN
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Capricor Therapeutics initiated at Overweight by Piper Sandler - MSN
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3%Here's Why - MarketBeat
Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics stock outlook driven by DMD drug potential, says Piper Sandler - Investing.com Canada
Cash raises for Inventiva, Akeso, Capricor - BioCentury
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Capricor Therapeutics Announces Closing of Underwritten - GlobeNewswire
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - StockTitan
Form 424B5 CAPRICOR THERAPEUTICS, - StreetInsider.com
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownHere's What Happened - MarketBeat
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):